Loading
A phase 3 trial of Durvalumab, Tremelimumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin is a phase 3 interventional study registered as NCT04960709 by AstraZeneca, with 712 participants enrolled, started 2021-08-05 and due to reach its primary completion in 2026-03-02. Interventions recorded: Durvalumab, Tremelimumab, Enfortumab Vedotin and Radical Cystectomy.
Shares Tremelimumab, Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca and the tag pipeline.
Shares Tremelimumab, Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.